VIRX - Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

PR Newswire

SAN DIEGO , April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21 ^st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022 , at 3:00 p.m. EDT .

A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts . The webcast will be archived for 30 days.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV ⁺ ) lymphoma (NAVAL-1) as well as a multinational, open-label Phase 1b /2 trial for the treatment of EBV ⁺ recurrent or metastatic nasopharyngeal carcinoma and other EBV ⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com .

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.